| Summary: | Prostate cancer is a common malignant tumor in men, which seriously endangers men's health.
At present, in the treatment of prostate cancer in different stages, the survival of patients
shows differences, and the survival rate of early prostate cancer is high. The prognosis is good,
the survival rate of advanced prostate cancer is low, and the prognosis is poor. Digital rectal
examination combined with serum PSA detection is currently recognized as the best method
for early prostate cancer screening. However, the specificity of PSA is poor, and a large number
of prostate cancer patients are overdiagnosed and overtreated. At the same time, the treatment
of advanced prostate cancer also needs more reliable biomarkers to judge the treatment effect
and assist clinical decision-making.
|
|---|
